We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $5.12B
1-Year Est. Return 314.02%
This Fund
S&P 500
This Quarter Est. Return
+17.47%
1 Year Est. Return
+314.02%
3 Year Est. Return
+1,498.66%
5 Year Est. Return
+2,457.67%
10 Year Est. Return
+48,821.41%
AUM
$3.02B
AUM Growth
+$399M
Cap. Flow
+$261M
Cap. Flow %
8.64%
Top 10 Hldgs %
52.67%
Holding
175
New
36
Increased
34
Reduced
22
Closed
43

Top Buys

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$50.4M
2
LJPC
La Jolla Pharmaceutical Company
LJPC
+$40.2M
3
MMSI icon
Merit Medical Systems
MMSI
+$32.5M
4
ABMD
Abiomed Inc
ABMD
+$30.5M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$24.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$57.5M
2
NXTM
NxStage Medical Inc.
NXTM
+$34.9M
3
TSRO
TESARO, Inc.
TSRO
+$25.4M
4
PBYI icon
Puma Biotechnology
PBYI
+$24.6M
5
AVXS
AveXis, Inc. Common Stock
AVXS
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 97.12%
2 Consumer Discretionary 0.06%
3 Technology 0.04%
4 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZLAB icon
76
Zai Lab
ZLAB
$2.07B
$3.71M 0.12%
175,000
– –
LUMO
77
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.65M 0.12%
50,000
– –
OCGN icon
78
Ocugen
OCGN
$403M
$3.64M 0.12%
29,630
– –
QTRX icon
79
Quanterix
QTRX
$159M
$3.64M 0.12%
+169,400
New +$3.31M
IVC
80
DELISTED
Invacare Corporation
IVC
$3.37M 0.11%
200,000
– –
ARAV
81
DELISTED
Aravive, Inc. Common Stock
ARAV
$3.27M 0.11%
248,027
-66,666
-21% -$858K
NEOS
82
DELISTED
Neos Therapeutics, Inc
NEOS
$3.06M 0.1%
+300,000
New +$2.88M
ACHN
83
DELISTED
Achillion Pharmaceuticals
ACHN
$2.88M 0.1%
+1,000,000
New +$3.63M
BLUE
84
DELISTED
bluebird bio
BLUE
$2.56M 0.09%
+1,112
New +$2.26M
ALNA
85
DELISTED
Allena Pharmaceuticals
ALNA
$2.52M 0.08%
+250,000
New +$3.08M
VRNA
86
DELISTED
Verona Pharma
VRNA
$2.38M 0.08%
200,000
– –
DCPH
87
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$2.32M 0.08%
102,500
– –
EIGR
88
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$2.2M 0.07%
5,256
– –
FRTX
89
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$2.09M 0.07%
+3,628
New +$2.39M
ACER
90
DELISTED
Acer Therapeutics Inc
ACER
$2.09M 0.07%
+150,000
New +$2.44M
SBBP
91
DELISTED
Strongbridge Biopharma plc.
SBBP
$1.99M 0.07%
+275,000
New +$1.72M
BCLI
92
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$1.57M 0.05%
26,667
– –
CSBR icon
93
Champions Oncology
CSBR
$75.9M
$1.5M 0.05%
386,540
– –
CRBP icon
94
Corbus Pharmaceuticals
CRBP
$165M
$1.42M 0.05%
6,667
-7,156
-52% -$1.53M
EXEL icon
95
Exelixis
EXEL
$13.9B
$1.41M 0.05%
46,361
– –
PFNX
96
DELISTED
Pfenex Inc.
PFNX
$1.38M 0.05%
519,773
-326,200
-39% -$903K
STLA icon
97
Stellantis
STLA
$17.4B
$1.11M 0.04%
62,000
– –
LNTH icon
98
Lantheus
LNTH
$6.51B
$1.1M 0.04%
53,763
– –
VCRA
99
DELISTED
VOCERA COMMUNICATIONS, INC.
VCRA
$1.06M 0.04%
+35,169
New +$1M
ABEO icon
100
Abeona Therapeutics
ABEO
$355M
$946K 0.03%
2,386
-2,290
-49% -$947K
2 3
4
5 6

Similar funds

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
TAM
Todd Asset Management Louisville, Kentucky $5.11B AUM 34.73% 1-Year Est. Return
CIA
Choate Investment Advisors Boston, Massachusetts $5.11B AUM 17.2% 1-Year Est. Return
AC
AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return
EIC
Equity Investment Corp Atlanta, Georgia $5.11B AUM 8.63% 1-Year Est. Return
CIC
Carnegie Investment Counsel Pepper Pike, Ohio $5.13B AUM 22.98% 1-Year Est. Return
CS
Cannell & Spears New York $5.1B AUM 31.77% 1-Year Est. Return
NC
Nicholas Company Milwaukee, Wisconsin $5.1B AUM 8.43% 1-Year Est. Return

Perceptive Advisors's Q4 2017 Portfolio in Review

As of Q4 2017, Perceptive Advisors held 175 positions worth $3.02B, up 15% from $2.62B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Perceptive Advisors deployed $261M of net new capital in Q4 2017, opening 36 new positions and adding to 34 existing holdings. Its largest new stake was Zimmer Biomet: 206,000 shares worth $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $57.5M trimmed.

  • Perceptive Advisors's largest Q4 2017 buy was Zimmer Biomet: 206,000 shares worth $24.1M.
  • Perceptive Advisors added most to Blueprint Medicines in Q4 2017, an estimated $50.4M increase.
  • Perceptive Advisors's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $57.5M.
  • Perceptive Advisors fully exited NxStage Medical Inc. in Q4 2017, selling an estimated $34.9M.
  • Perceptive Advisors's ten largest holdings make up 53% of its $3.02B portfolio in Q4 2017.
  • Perceptive Advisors opened 36 new positions and closed 43 in Q4 2017.
  • Perceptive Advisors's portfolio value rose 15% quarter-over-quarter to $3.02B.

Based on Perceptive Advisors's 13F filing for Q4 2017, filed 14 Feb 2018.